tirzepatide bmi Shifts in body mass index category with and associated changes in cardiometabolic risk factors in people with obesity: a post hoc analysis from the SURMOUNT-1 and SURMOUNT-4 trials Who Is a Good Candidate

Step-therapy mandates that patients fail metformin or orlistat add 36 months to initiation timelines, increasing dropout risk

No significant associations were found for any OMM (Table 1)

Look for cloudiness, visible particles, color changes (beyond very faint yellow), unusual smell, or foam that will not dissipate

I decided that if the drug was going to strip muscle, I would out-train it and out-eat it

When initiating tirzepatide in patients taking insulin or sulfonylureas, dose reductions of these medications should be considered to reduce hypoglycemia risk, though this decision should be made in consultation with your healthcare provider

Cell Probes 30 , 386396 (2016)